Comparative Pharmacology
Head-to-head clinical analysis: INTAL versus NASALCROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INTAL versus NASALCROM.
INTAL vs NASALCROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mast cell stabilizer; inhibits degranulation of sensitized mast cells by blocking release of histamine and other inflammatory mediators.
Cromolyn sodium stabilizes mast cells by inhibiting the release of histamine and other mediators of inflammation from sensitized mast cells. The exact molecular mechanism is not fully understood but may involve inhibition of calcium ion influx into mast cells.
2 inhalations (2 mg each) via nebulizer 4 times daily; or 20 mg via inhalation powder (Spinhaler) 4 times daily.
One spray (5.2 mg) into each nostril 3-4 times daily (maximum 6 times daily).
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in plasma; clinical effect persists longer due to mast cell stabilization in airways.
Terminal elimination half-life is 1-2 hours; clinically, due to local mast cell stabilization, systemic levels do not correlate with effect.
Primarily renal: unchanged drug (50-70%) and conjugated metabolites (20-30%); biliary/fecal: <5%.
Primarily unchanged drug; renal excretion accounts for ~90% of elimination, with minor biliary/fecal excretion (<5%).
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer